Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06797011 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy of Plasmapheresis in Patients of Drug-Induced Liver Injury (DILI) With Underlying Chronic Liver Disease

StatusNot Yet Recruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 28, 2025 (before its estimated January 31, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
DILI is an underdiagnosed and under appreciated causal or contributing factor to liver injury. DILI can mimics features of the entire spectrum of acute and chronic liver disease. Asia-Pacifc region is characterized by two unique features; the high prevalence of tuberculosis (TB) in the population and the ubiquitous use of traditional and complimentary medicines.Current definition of Hy's law presents significant difficulties when dealing with patients with preexisting CLD in clinical trials. Hallmark of the hepatic manifestation in these patients is hyperbilirubinemia and coagulopathy rather than ALT elevation.
Trial Details
NCT Number NCT06797011
Lead Sponsor Institute of Liver and Biliary Sciences, India
Conditions
(from sponsor)		 Drug Induced Liver Injury, Chronic Liver Disease
Related terms Chemical and Drug Induced Liver Injury
Enrollment 96 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov